S.Amdt. 3376

SA 3376. Mr. KAINE (for himself and Mrs. Capito) submitted an
amendment intended to be proposed by him to the bill S. 524, to
authorize the Attorney General to award grants to address the national
epidemics of prescription opioid abuse and heroin use; which was
ordered to lie on the table; as follows:

On page 67, line 24, insert ``including best practices on
the co-prescribing of naloxone'' after ``guidelines''.
On page 77, between lines 5 and 6, insert the following:

SEC. __. NALOXONE CO-PRESCRIBING IN FEDERAL HEALTH CARE AND
MEDICAL FACILITIES.

(a) Naloxone Co-Prescribing Guidelines.--Not later than 180
days after the date of enactment of this Act:
(1) The Secretary of Health and Human Services shall, as
appropriate, provide information to prescribers within
Federally qualified health centers (as defined in paragraph
(4) of section 1861(aa) of the Social Security Act (42 U.S.C.
1395x(aa))), and the health care facilities of the Indian
Health Service, on best practices for co-prescribing naloxone
for patients receiving chronic opioid therapy and patients
being treated for opioid use disorders.
(2) The Secretary of Defense shall, as appropriate, provide
information to prescribers within Department of Defense
medical facilities on best practices for co-prescribing
naloxone for patients receiving chronic opioid therapy and
patients being treated for opioid use disorders.
(3) The Secretary of Veterans Affairs shall, as
appropriate, provide information to prescribers within
Department of Veterans Affairs medical facilities on best
practices for co-prescribing naloxone for patients receiving
chronic opioid therapy and patients being treated for opioid
use disorders.
(b) Definitions.--In this section:
(1) Co-prescribing.--The term ``co-prescribing'' means,
with respect to an opioid overdose reversal drug, the
practice of prescribing such drug in conjunction with an
opioid prescription for patients at an elevated risk of
overdose, or in conjunction with an opioid agonist approved
under section 505 of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 355) for the treatment of opioid use disorders, or
in other circumstances in which a provider identifies a
patient at an elevated risk for an intentional or
unintentional drug overdose from heroin or prescription
opioid therapies.
(2) Elevated risk of overdose.--The term ``elevated risk of
overdose'' has the meaning given such term by the Secretary
of Health and Human Services, which--
(A) may be based on the criteria provided in the Opioid
Overdose Toolkit published by the Substance Abuse and Mental
Health Services Administration; and
(B) may include patients on a first course opioid
treatment, patients using extended-release and long-acting
opioid analgesic, and patients with a respiratory disease or
other co-morbidities.
______